Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy

NEXT STORY
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
PREV STORY
Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Adicet Bio Announces Formation of Scientific Advisory Board

author_avatar
NASDAQ Market News

ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine

YONKERS, N.Y., Feb. 13, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology ...

author_avatar
NASDAQ Market News

Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease

author_avatar
NASDAQ Market News